Balchem (BCPC) 10-Q 30 Jul 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 22, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	1-13648
Entity Registrant Name	Balchem Corporation
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	13-2578432
Entity Address, Address Line One	52 Sunrise Park Road
Entity Address, City or Town	New Hampton
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10958
City Area Code	845
Local Phone Number	326-5600
Title of 12(b) Security	Common Stock, par value $.06-2/3 per share
Trading Symbol	BCPC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,370,535
Entity Central Index Key	0000009326
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 79,902	$ 84,571
Accounts receivable, net of allowance for doubtful accounts of $1,074 and $2,092 at June 30, 2021 and December 31, 2020 respectively	113,782	98,214
Inventories	78,333	70,620
Prepaid expenses	8,140	6,598
Prepaid income taxes	2,520	3,447
Other current assets	4,586	3,438
Total current assets	287,263	266,888
Property, plant and equipment, net	228,289	228,096
Goodwill	527,148	529,463
Intangible assets with finite lives, net	108,253	121,660
Right of use assets	9,575	8,410
Other assets	13,078	11,326
Total assets	1,173,606	1,165,843
Current liabilities:
Trade accounts payable	44,804	23,742
Accrued expenses	39,576	29,655
Accrued compensation and other benefits	13,887	19,753
Dividends payable	203	18,941
Lease liabilities - current	2,289	2,337
Total current liabilities	100,759	94,428
Revolving loan	123,569	163,569
Deferred income taxes	51,883	51,359
Lease liabilities - non-current	7,395	6,079
Derivative liabilities	7,662	11,658
Other long-term obligations	12,696	10,517
Total liabilities	303,964	337,610
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,470,829 shares issued and 32,404,774 shares outstanding at June 30, 2021 and 32,448,705 shares issued and 32,372,621 outstanding at December 31, 2020, respectively	2,165	2,164
Additional paid-in capital	172,635	173,029
Retained earnings	702,882	656,740
Accumulated other comprehensive income	432	4,173
Treasury stock, at cost: 66,055 and 76,084 shares at June 30, 2021 and December 31, 2020, respectively	(8,472)	(7,873)
Total stockholders' equity	869,642	828,233
Total liabilities and stockholders' equity	$ 1,173,606	$ 1,165,843

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Allowance for doubtful accounts	$ 1,074	$ 2,092
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,470,829	32,448,705
Common stock, shares outstanding (in shares)	32,404,774	32,372,621
Treasury stock (in shares)	66,055	76,084

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net sales	$ 202,365	$ 173,355	$ 388,021	$ 347,791
Cost of sales	142,918	117,975	269,847	237,080
Gross margin	59,447	55,380	118,174	110,711
Operating expenses:
Selling expenses	14,846	13,836	29,770	29,266
Research and development expenses	2,899	2,569	5,648	5,269
General and administrative expenses	11,109	12,058	21,588	22,981
Total operating expenses	28,854	28,463	57,006	57,516
Earnings from operations	30,593	26,917	61,168	53,195
Other expenses:
Interest expense, net	608	960	1,333	2,656
Other (income) expense, net	(34)	(16)	(167)	76
Total other expenses (income)	574	944	1,166	2,732
Earnings before income tax expense	30,019	25,973	60,002	50,463
Income tax expense	7,288	4,848	13,860	9,570
Net earnings	$ 22,731	$ 21,125	$ 46,142	$ 40,893
Net earnings per common share - basic (in dollars per share)	$ 0.71	$ 0.66	$ 1.43	$ 1.27
Net earnings per common share - diluted (in dollars per share)	$ 0.70	$ 0.65	$ 1.41	$ 1.26

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net earnings	$ 22,731	$ 21,125	$ 46,142	$ 40,893
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	1,524	2,346	(4,619)	3,127
Unrealized gain (loss) on cash flow hedge	351	221	863	(2,886)
Change in postretirement benefit plans	8	8	15	(571)
Other comprehensive income (loss)	1,883	2,575	(3,741)	(330)
Comprehensive income	$ 24,614	$ 23,700	$ 42,401	$ 40,563

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Treasury Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2019	$ 743,667	$ 590,921	$ (5,564)	$ 2,161	$ (18,069)	$ 174,218
Beginning balance, common stock (in shares) at Dec. 31, 2019				32,405,796	(203,879)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	19,768	19,768
Other comprehensive income (loss)	(2,905)		(2,905)
Treasury shares purchased	(891)				$ (891)
Treasury shares purchased (in shares)					(8,224)
Shares and options (cancelled) issued under stock plans	6,632			$ 3	$ 7,266	(637)
Shares and options (cancelled) issued under stock plans (in shares)				41,619	81,530
Ending balance at Mar. 31, 2020	766,271	610,689	(8,469)	$ 2,164	$ (11,694)	173,581
Ending balance, common stock (in shares) at Mar. 31, 2020				32,447,415	(130,573)
Beginning balance at Dec. 31, 2019	743,667	590,921	(5,564)	$ 2,161	$ (18,069)	174,218
Beginning balance, common stock (in shares) at Dec. 31, 2019				32,405,796	(203,879)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	40,893
Other comprehensive income (loss)	(330)
Ending balance at Jun. 30, 2020	792,523	631,814	(5,894)	$ 2,164	$ (9,634)	174,073
Ending balance, common stock (in shares) at Jun. 30, 2020				32,451,415	(109,919)
Beginning balance at Mar. 31, 2020	766,271	610,689	(8,469)	$ 2,164	$ (11,694)	173,581
Beginning balance, common stock (in shares) at Mar. 31, 2020				32,447,415	(130,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	21,125	21,125
Other comprehensive income (loss)	2,575		2,575
Treasury shares purchased	(2,134)				$ (2,134)
Treasury shares purchased (in shares)					(24,281)
Shares and options (cancelled) issued under stock plans	4,686				$ 4,194	492
Shares and options (cancelled) issued under stock plans (in shares)				4,000	44,935
Ending balance at Jun. 30, 2020	792,523	631,814	(5,894)	$ 2,164	$ (9,634)	174,073
Ending balance, common stock (in shares) at Jun. 30, 2020				32,451,415	(109,919)
Beginning balance at Dec. 31, 2020	828,233	656,740	4,173	$ 2,164	$ (7,873)	173,029
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,448,705	(76,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	23,411	23,411
Other comprehensive income (loss)	(5,624)		(5,624)
Treasury shares purchased	(1,596)				$ (1,596)
Treasury shares purchased (in shares)					(13,475)
Shares and options (cancelled) issued under stock plans	5,068			$ 1	$ 7,259	(2,192)
Shares and options (cancelled) issued under stock plans (in shares)				22,314	70,470
Ending balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	$ (2,210)	170,837
Ending balance, common stock (in shares) at Mar. 31, 2021				32,471,019	(19,089)
Beginning balance at Dec. 31, 2020	828,233	656,740	4,173	$ 2,164	$ (7,873)	173,029
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,448,705	(76,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	46,142
Other comprehensive income (loss)	(3,741)		(3,741)
Ending balance at Jun. 30, 2021	869,642	702,882	432	$ 2,165	$ (8,472)	172,635
Ending balance, common stock (in shares) at Jun. 30, 2021				32,470,829	(66,055)
Beginning balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	$ (2,210)	170,837
Beginning balance, common stock (in shares) at Mar. 31, 2021				32,471,019	(19,089)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	22,731	22,731
Other comprehensive income (loss)	1,883		1,883
Treasury shares purchased	(9,240)				$ (9,240)
Treasury shares purchased (in shares)					(72,649)
Shares and options (cancelled) issued under stock plans	4,776				$ 2,978	1,798
Shares and options (cancelled) issued under stock plans (in shares)				(190)	25,683
Ending balance at Jun. 30, 2021	$ 869,642	$ 702,882	$ 432	$ 2,165	$ (8,472)	$ 172,635
Ending balance, common stock (in shares) at Jun. 30, 2021				32,470,829	(66,055)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings	$ 46,142	$ 40,893
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	24,463	25,294
Stock compensation expense	5,914	4,501
Deferred income taxes	54	386
Provision for doubtful accounts	(25)	329
Unrealized (gain)/loss on foreign currency transaction and deferred compensation	(401)	30
Asset impairment charge	0	1,915
(Gain)/Loss on disposal of assets	(19)	37
Changes in assets and liabilities
Accounts receivable	(16,361)	(4,164)
Inventories	(7,949)	2,339
Prepaid expenses and other current assets	(2,859)	(1,970)
Accounts payable and accrued expenses	25,873	(9,191)
Income taxes	898	7,404
Other	659	(623)
Net cash provided by operating activities	76,389	67,180
Cash flows from investing activities:
Capital expenditures and intangible assets acquired	(13,760)	(13,265)
Proceeds from sale of assets	240	22
Purchase of convertible note	0	(350)
Net cash used in investing activities	(13,520)	(13,593)
Cash flows from financing activities:
Proceeds from revolving loan	5,000	10,000
Principal payments on revolving loan	(45,000)	(40,000)
Principal payments on finance lease	(78)	0
Proceeds from stock options exercised	3,886	6,802
Dividends paid	(18,700)	(16,704)
Purchase of treasury stock	(10,835)	(3,025)
Net cash used in financing activities	(65,727)	(42,927)
Effect of exchange rate changes on cash	(1,811)	75
(Decrease) increase in cash and cash equivalents	(4,669)	10,735
Cash and cash equivalents beginning of period	84,571	65,672
Cash and cash equivalents end of period	$ 79,902	$ 76,407

CONDENSED CONSOLIDATED FINANCIA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The condensed consolidated financial statements presented herein have been prepared in accordance with the accounting policies described in its December 31, 2020 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated financial statements reflect the operations of Balchem Corporation and its subsidiaries (the "Company"). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the operating results expected for the full year or any interim period. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this standards update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued Accounting Standards Update ("ASU") 2021-01, "Reference Rate Reform (Topic 848): Scope." This ASU clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company is currently evaluating the impact of this pronouncement on the consolidated financial statements and disclosures. Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." The amendments in this Update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new standard on January 1, 2021. The standard did not have a significant impact on the Company's consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company's consolidated financial statements and disclosures. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The Company adopted the new standard and related updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY STOCK-BASED COMPENSATION The Company’s results for the three and six months ended June 30, 2021 and 2020 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Increase/(Decrease) for the Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of sales $ 444 $ 310 $ 744 $ 575 Operating expenses 2,849 2,010 5,170 3,926 Net earnings (2,547) (1,756) (4,569) (3,419) As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest. The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of June 30, 2021, the plans had 687,297 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three three Option activity for the six months ended June 30, 2021 and 2020 is summarized below: For the six months ended June 30, 2021 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.12 Exercised (58) 65.95 Forfeited (2) 101.38 Canceled (1) 74.57 Outstanding as of June 30, 2021 926 $ 86.85 $ 41,107 6.8 Exercisable as of June 30, 2021 580 $ 73.72 $ 33,398 5.6 For the six months ended June 30, 2020 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2019 951 $ 68.18 $ 31,814 Granted 145 111.94 Exercised (130) 52.54 Forfeited (4) 89.90 Canceled — — Outstanding as of June 30, 2020 962 $ 76.78 $ 19,915 6.5 Exercisable as of June 30, 2020 618 $ 66.68 $ 17,418 5.3 ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 33% and 26%; risk-free interest rates of 0.5% and 1.4%; and expected lives of 4.9 years and 3.7 years, in each case for the six months ended June 30, 2021 and 2020, respectively. The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury Zero coupon issues with a remaining term equal to the expected life. Other information pertaining to option activity during the three and six months ended June 30, 2021 and 2020 was as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 Weighted-average fair value of options granted $ 34.42 $ — $ 33.11 $ 23.05 Total intrinsic value of stock options exercised ($000s) $ 1,814 $ 2,351 $ 3,731 $ 6,371 Non-vested restricted stock activity for the six months ended June 30, 2021 and 2020 is summarized below: Six Months Ended June 30, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 159 $ 90.71 138 $ 80.03 Granted 37 119.30 35 110.72 Vested (13) 87.33 (20) 67.59 Forfeited (2) 85.60 (1) 86.82 Non-vested balance as of June 30 181 $ 96.89 152 $ 89.22 Non-vested performance share activity for the six months ended June 30, 2021 and 2020 is summarized below: Six Months Ended June 30, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 71 $ 91.99 70 $ 81.26 Granted 36 108.74 20 126.46 Vested (24) 70.64 (8) 104.15 Forfeited (11) 74.57 (11) 82.71 Non-vested balance as of June 30 72 $ 110.22 71 $ 91.99 The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 0.2% and 1.4%; dividend yields of 0.6% and 0.5%; volatilities of 33% and 24%; and initial TSR’s of 11.7% and 10.9%, in each case for the six months ended June 30, 2021 and 2020, respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. As of June 30, 2021 and 2020, there was $19,796 and $17,034, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of June 30, 2021, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.6 years. The Company estimates that share-based compensation expense for the year ended December 31, 2021 will be approximately $11,400. REPURCHASE OF COMMON STOCK The Company has an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,654,520 shares have been purchased, of which 66,055 shares remained in treasury at June 30, 2021. The Company repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. The Company also intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. During the six months ended June 30, 2021 and 2020, the Company purchased 86,124 and 32,505 shares, respectively, from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes and from open market purchases. These shares were purchased at an average cost of $125.81 and $93.05, respectively.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories at June 30, 2021 and December 31, 2020 consisted of the following: June 30, 2021 December 31, 2020 Raw materials $ 25,119 $ 24,536 Work in progress 9,682 3,050 Finished goods 43,532 43,034 Total inventories $ 78,333 $ 70,620

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at June 30, 2021 and December 31, 2020 are summarized as follows: June 30, 2021 December 31, 2020 Land $ 11,988 $ 12,215 Building 88,224 86,873 Equipment 250,596 247,884 Construction in progress 37,941 31,240 388,749 378,212 Less: accumulated depreciation 160,460 150,116 Property, plant and equipment, net $ 228,289 $ 228,096

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The Company had goodwill in the amount of $527,148 and $529,463 as of June 30, 2021 and December 31, 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is due to foreign exchange translation adjustments. Identifiable intangible assets with finite lives at June 30, 2021 and December 31, 2020 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at 6/30/2021 Gross Carrying Amount at 12/31/2020 Accumulated Amortization at 12/31/2020 Customer relationships & lists 10-20 $ 242,089 $ 165,886 $ 243,557 $ 158,051 Trademarks & trade names 2-17 43,169 27,112 43,208 24,974 Developed technology 5-12 20,351 14,210 20,437 13,693 Other 2-18 23,454 13,602 22,861 11,685 $ 329,063 $ 220,810 $ 330,063 $ 208,403

EQUITY-METHOD INVESTMENT

EQUITY-METHOD INVESTMENT	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company receives up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a lo ss of $130 and $274 for the three and six months ended June 30, 2021, respectively, and $142 and $280 for the three and six months ended June 30, 2020, respectively, relating to its portion of the joint venture's expenses in other expense. The Company received a net return of capital totaling $28 and $15 fo r the three and six months ended June 30, 2021, respectively, and made capital contributions to the investment totaling $131 and $798 for the three and six months ended June 30, 2020, respectively. The carrying value of the joint venture at June 30, 2021 and December 31, 2020 is $4,682 and $4,971, respectively, and is recorded in other assets.

REVOLVING LOAN

REVOLVING LOAN	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
REVOLVING LOAN	REVOLVING LOAN On June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "Credit Agreement"), which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000. The Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”). The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. As of June 30, 2021 and December 31, 2020 , the total balance outstanding on the Credit Agreement amounted to $123,569 and $163,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 1.095% at June 30, 2021. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% (0.15% at June 30, 2021). The unused portion of the revolving loan amounted to $376,431 at June 30, 2021. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders. Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement, which is not materially different than the effective interest method. Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $562 and $703 at June 30, 2021 and December 31, 2020, respectively, and are included in other assets on the condensed consolidated balance sheets. Amortization expense pertaining to these costs totaled $70 and $141, for both the three and six months ended June 30, 2021 and 2020, and are included in interest expense in the accompanying condensed consolidated statements of earnings. The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At June 30, 2021, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements are secured by assets of the Company.

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
NET EARNINGS PER SHARE	NET EARNINGS PER SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended Six Months Ended 2021 2020 2021 2020 Net Earnings - Basic and Diluted $ 22,731 $ 21,125 $ 46,142 $ 40,893 Shares (000s) Weighted Average Common Shares - Basic 32,232 32,180 32,243 32,158 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 419 290 410 334 Weighted Average Common Shares - Diluted 32,651 32,470 32,653 32,492 Net Earnings Per Share - Basic $ 0.71 $ 0.66 $ 1.43 $ 1.27 Net Earnings Per Share - Diluted $ 0.70 $ 0.65 $ 1.41 $ 1.26 The number of anti-dilutive shares were 153,868 and 304,324 for the three and six months ended June 30, 2021, respectively, and 377,573 and 212,271 for the three and six months ended June 30, 2020 , respectively. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended June 30, 2021 and 2020, was 24.3% and 18.7%, respectively, and 23.1% and 19.0% for the six months ended June 30, 2021 and 2020. The increase in the effective tax rate for the three months ended June 30, 2021 compared to the three months ended June 30, 2020 was primarily due to a reduction in certain tax credits and lower tax benefits from stock-based compensation. The increase in the effective tax rate for the six months ended June 30, 2021 compared to the six months ended June 30, 2020 was primarily due to a reduction in certain tax credits, lower tax benefits from stock-based compensation, and higher enacted state tax rates. On March 27, 2020, Congress passed the Coronavirus Aid, Relief, and Economic Security Act, and on December 27, 2020, Congress passed an additional round of COVID relief legislation as part of the Bipartisan-Bicameral Omnibus COVID Relief Deal. The Company has reviewed the change in law and determined that it does not have a significant impact on the Company’s tax provision or financial statements. In addition, Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the Securities and Exchange Commission ("SEC"), and/or the Financial Accounting Standards Board ("FASB") regarding this act. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences. The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of June 30, 2021, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2016. As of June 30, 2021 and December 31, 2020, the Company had approximately $5,465 and $5,335, respectively, of

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated." Human Nutrition & Health The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Animal Nutrition & Health The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials. The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder drum and cylinder packaging approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment. The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate ® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. The segment information is summarized as follows: Business Segment Assets June 30, December 31, Human Nutrition & Health $ 721,428 $ 717,232 Animal Nutrition & Health 156,597 157,454 Specialty Products 194,140 190,449 Other and Unallocated (1) 101,441 100,708 Total $ 1,173,606 $ 1,165,843 Business Segment Net Sales Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 111,471 $ 97,428 $ 215,987 $ 192,936 Animal Nutrition & Health 54,481 46,344 105,629 94,985 Specialty Products 34,022 28,194 62,030 56,190 Other and Unallocated (2) 2,391 1,389 4,375 3,680 Total $ 202,365 $ 173,355 $ 388,021 $ 347,791 Business Segment Earnings Before Income Taxes Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 19,021 $ 15,497 $ 38,711 $ 27,632 Animal Nutrition & Health 3,561 6,430 8,617 14,474 Specialty Products 9,729 8,008 16,918 15,994 Other and Unallocated (2) (1,718) (3,018) (3,078) (4,905) Interest and other expense (574) (944) (1,166) (2,732) Total $ 30,019 $ 25,973 $ 60,002 $ 50,463 Depreciation/Amortization Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 7,441 $ 8,015 $ 15,014 $ 15,859 Animal Nutrition & Health 1,816 1,793 3,580 3,548 Specialty Products 2,085 2,372 4,354 4,764 Other and Unallocated (2) 757 565 1,515 1,123 Total $ 12,099 $ 12,745 $ 24,463 $ 25,294 Capital Expenditures Six Months Ended 2021 2020 Human Nutrition & Health $ 8,883 $ 8,884 Animal Nutrition & Health 2,729 2,446 Specialty Products 1,448 958 Other and Unallocated (2) 66 87 Total $ 13,126 $ 12,375 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $466 and $700 for the three and six months ended June 30, 2021, respectively, and $746 and $2,018 for the three and six months ended June 30, 2020, respectively, and (ii) Unallocated amortization expense of $674 and $1,349 for the three and six months ended June 30, 2021, respectively, and $475 and $947 for the three and six months ended June 30, 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in the Company's consolidated statement of earnings.

REVENUE

REVENUE	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods. The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended Six Months Ended 2021 2020 2021 2020 Product Sales $ 193,122 $ 163,038 $ 369,110 $ 330,603 Co-manufacturing 6,878 8,135 14,156 13,376 Bill and Hold — 395 — 395 Consignment 1,380 695 2,431 1,314 Product Sales Revenue 201,380 172,263 385,697 345,688 Royalty Revenue 985 1,092 2,324 2,103 Total Revenue $ 202,365 $ 173,355 $ 388,021 $ 347,791 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended Six Months Ended 2021 2020 2021 2020 United States $ 147,188 $ 122,236 $ 285,039 $ 249,145 Foreign Countries 55,177 51,119 102,982 98,646 Total Revenue $ 202,365 $ 173,355 $ 388,021 $ 347,791 Product Sales Revenues The Company’s primary operation is the manufacturing and sale of health and nutrition ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of four sub-streams: product sales, co-manufacturing, bill and hold, and consignment. Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials. The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer. Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided. Royalty Revenues Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment. Contract Liabilities The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable. The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the six months ended June 30, 2021 and 2020 for income taxes and interest is as follows: Six Months Ended 2021 2020 Income taxes $ 12,493 $ 555 Interest $ 2,452 $ 2,580

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The changes in accumulated other comprehensive income/(loss) were as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 Net foreign currency translation adjustment $ 1,524 $ 2,346 $ (4,619) $ 3,127 Net change of cash flow hedge (see Note 19 for further information) Unrealized gain (loss) on cash flow hedge 456 49 1,133 (3,884) Tax (105) 172 (270) 998 Net of tax 351 221 863 (2,886) Net change in postretirement benefit plan (see Note 14 for further information) Amortization of prior service cost 19 19 37 38 Amortization of gain (7) (13) (12) (26) Prior service credit — — (4) — Total before tax 12 6 21 12 Tax (4) 2 (6) 1 Adjustment (1) — — — (584) Net of tax and adjustment 8 8 15 (571) Total other comprehensive income (loss) $ 1,883 $ 2,575 $ (3,741) $ (330) (1) One time adjustment to the postretirement account. Included in "Net foreign currency translation adjustment" was a loss of $1,024 and a gain of $2,173, related to a net investment hedge, which were net of taxes of $336 and $690 for the three and six months ended June 30, 2021, respectively. Included in "Net foreign currency translation adjustment" w as a loss of $1,514 and a gain of $2,905, re lated to a net investment hedge, which were net of taxes of $260 and $914 for the three and six months ended June 30, 2020, respectively. See Note 19, "Derivative Instruments and Hedging Activities." Accumulated other comprehensive income/(loss) at June 30, 2021 and December 31, 2020 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2020 $ 7,653 $ (3,684) $ 204 $ 4,173 Other comprehensive income/(loss) (4,619) 863 15 (3,741) Balance June 30, 2021 $ 3,034 $ (2,821) $ 219 $ 432

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Defined Contribution Plans The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1st, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. Postretirement Medical Plans The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement. Net periodic benefit costs for such retirement medical plans were as follows: Six Months Ended 2021 2020 Service cost $ 43 $ 34 Interest cost 12 13 Amortization of prior service cost 37 38 Amortization of gain (12) (26) Net periodic benefit cost $ 80 $ 59 T he amount recorded for these obligations on the Company’s balance sheets as of June 30, 2021 and December 31, 2020 is $1,429 and $1,374, respectively, and are included in other long-term obligations. These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plans have typically been less than $100 per year. Defined Benefit Pension Plans On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on the Company's consolidated balance sheet as of June 30, 2021 and December 31, 2020 were $945 and $950, respectively, and were included in other long-term obligations. Six Months Ended 2021 2020 Service cost with interest to end of year $ 35 $ 52 Interest cost 7 10 Expected return on plan assets (18) (8) Amortization of gain 2 — Total net periodic benefit cost $ 26 $ 54 Deferred Compensation Plan

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at June 30, 2021 are as follows: Year July 1, 2021 to December 31, 2021 $ 2,118 2022 3,022 2023 2,381 2024 1,578 2025 972 2026 664 Thereafter 2,414 Total minimum lease payments $ 13,149 The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the facility for potential liabilities associated with the Superfund site. In September 2020, BCP Ingredients, Inc. ("BCP"), the Company subsidiary that operates the site, received a General Notice Letter from the EPA regarding BCP's potential liability for 1,4 dioxane contamination at the site. BCP currently believes that the 1,4 dioxane contamination is associated with the former owner’s operations and has engaged experts to study site conditions and hydrogeology in connection with preparing its response to the notice. From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at June 30, 2021 and December 31, 2020 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at June 30, 2021 and December 31, 2020 includes $814 and $817 in money market funds, respectively. Non-current assets at June 30, 2021 and December 31, 2020 includes $5,714 and $3,581, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds ar e valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties. As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings. Payments for the services the Company provided amounted to $920 and $1,747 for the three and six months ended June 30, 2021, respectively, and $857 and $1,710 for the three and six months ended June 30, 2020, respectively. The raw materials purchased and subsequently sold amounted to $6,580 and $12,042 for the three and six months ended June 30, 2021, respectively, and $2,903 and $7,614 for the three and six months ended June 30, 2020, respectively. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $5,210 and $9,601 for the three and six months ended June 30, 2021, respectively, and $3,020 and $6,741 for the three and six months ended June 30, 2020, respectively. At June 30, 2021 and December 31, 2020, the Company had receivables of $7,423 and $2,809, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. The Company also had payables of $5,182 and $2,239, respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had receivables in the amount of $72 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from June 30, 2021. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At June 30, 2021 and December 31, 2020, the Company had finance lease liabilities of $2,553 and $2,631, respectively, which were recorded under lease liabilities (current and non-current) in the consolidated balance sheet. Right of use assets and lease liabilities at June 30, 2021 and December 31, 2020 are summarized as follows: Right of use assets June 30, 2021 December 31, 2020 Operating leases $ 7,108 $ 5,838 Finance leases 2,467 2,572 Total $ 9,575 $ 8,410 Lease liabilities - current June 30, 2021 December 31, 2020 Operating leases $ 2,126 $ 2,178 Finance leases 163 159 Total $ 2,289 $ 2,337 Lease liabilities - non-current June 30, 2021 December 31, 2020 Operating leases $ 5,005 $ 3,607 Finance leases 2,390 2,472 Total $ 7,395 $ 6,079 For the three and six months ended June 30, 2021 and 2020, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Six Months Ended 2021 2020 2021 2020 Lease Cost Operating lease cost $ 770 $ 736 $ 1,486 $ 1,477 Finance Lease cost Amortization of ROU asset 53 — 105 — Interest on lease liabilities 33 — 66 — Total finance lease 86 — 171 — Total lease cost $ 856 $ 736 $ 1,657 $ 1,477 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 749 $ 739 $ 1,488 $ 1,483 Operating cash flows from finance leases 33 — 66 — Financing cash flows from finance leases 39 — 78 — $ 821 $ 739 $ 1,632 $ 1,483 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 1,376 $ (107) $ 2,412 $ (98) Weighted-average remaining lease term - operating leases 4.43 years 5.01 years 4.43 years 5.01 years Weighted-average remaining lease term - finance leases 11.75 years n/a 11.75 years n/a Weighted-average discount rate - operating leases 3.9 % 4.6 % 3.9 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a 5.1 % n/a
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from June 30, 2021. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At June 30, 2021 and December 31, 2020, the Company had finance lease liabilities of $2,553 and $2,631, respectively, which were recorded under lease liabilities (current and non-current) in the consolidated balance sheet. Right of use assets and lease liabilities at June 30, 2021 and December 31, 2020 are summarized as follows: Right of use assets June 30, 2021 December 31, 2020 Operating leases $ 7,108 $ 5,838 Finance leases 2,467 2,572 Total $ 9,575 $ 8,410 Lease liabilities - current June 30, 2021 December 31, 2020 Operating leases $ 2,126 $ 2,178 Finance leases 163 159 Total $ 2,289 $ 2,337 Lease liabilities - non-current June 30, 2021 December 31, 2020 Operating leases $ 5,005 $ 3,607 Finance leases 2,390 2,472 Total $ 7,395 $ 6,079 For the three and six months ended June 30, 2021 and 2020, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Six Months Ended 2021 2020 2021 2020 Lease Cost Operating lease cost $ 770 $ 736 $ 1,486 $ 1,477 Finance Lease cost Amortization of ROU asset 53 — 105 — Interest on lease liabilities 33 — 66 — Total finance lease 86 — 171 — Total lease cost $ 856 $ 736 $ 1,657 $ 1,477 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 749 $ 739 $ 1,488 $ 1,483 Operating cash flows from finance leases 33 — 66 — Financing cash flows from finance leases 39 — 78 — $ 821 $ 739 $ 1,632 $ 1,483 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 1,376 $ (107) $ 2,412 $ (98) Weighted-average remaining lease term - operating leases 4.43 years 5.01 years 4.43 years 5.01 years Weighted-average remaining lease term - finance leases 11.75 years n/a 11.75 years n/a Weighted-average discount rate - operating leases 3.9 % 4.6 % 3.9 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a 5.1 % n/a

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with the JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap (net investment hedge) with the JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. The net interest expense related to the interest rate swap contract was $534 and $1,055 for the three and six months ended June 30, 2021, and $430 and $551 for the three and six months ended June 30, 2020, respectively, were recorded in the condensed consolidated statements of operations under interest expense, net. At the same time, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $563 and $1,119 for the three and six months ended June 30, 2021, and $581 and $1,144 for the three and six months ended June 30, 2020, respectively, which were recorded in the condensed consolidated statements of operations under interest expense, net. The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheets. As of June 30, 2021 and December 31, 2020, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative liabilities June 30, 2021 December 31, 2020 Interest rate swap $ 3,732 $ 4,865 Cross-currency swap 3,930 6,793 Derivative liabilities $ 7,662 $ 11,658 On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting. As of June 30, 2021, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income. Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and six months ended June 30, 2021 and 2020: Location within Statements of Comprehensive Income Three Months Ended Six Months Ended 2021 2020 2021 2020 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 351 $ 221 $ 863 $ (2,886) Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment (1,024) (1,514) 2,173 2,905 Total $ (673) $ (1,293) $ 3,036 $ 19

CONDENSED CONSOLIDATED FINANC_2

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Policies)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this standards update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued Accounting Standards Update ("ASU") 2021-01, "Reference Rate Reform (Topic 848): Scope." This ASU clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company is currently evaluating the impact of this pronouncement on the consolidated financial statements and disclosures. Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." The amendments in this Update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new standard on January 1, 2021. The standard did not have a significant impact on the Company's consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company's consolidated financial statements and disclosures. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The Company adopted the new standard and related updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost on Net Earnings	The Company’s results for the three and six months ended June 30, 2021 and 2020 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Increase/(Decrease) for the Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of sales $ 444 $ 310 $ 744 $ 575 Operating expenses 2,849 2,010 5,170 3,926 Net earnings (2,547) (1,756) (4,569) (3,419)
Schedule of Stock Option Activity	Option activity for the six months ended June 30, 2021 and 2020 is summarized below: For the six months ended June 30, 2021 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.12 Exercised (58) 65.95 Forfeited (2) 101.38 Canceled (1) 74.57 Outstanding as of June 30, 2021 926 $ 86.85 $ 41,107 6.8 Exercisable as of June 30, 2021 580 $ 73.72 $ 33,398 5.6 For the six months ended June 30, 2020 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2019 951 $ 68.18 $ 31,814 Granted 145 111.94 Exercised (130) 52.54 Forfeited (4) 89.90 Canceled — — Outstanding as of June 30, 2020 962 $ 76.78 $ 19,915 6.5 Exercisable as of June 30, 2020 618 $ 66.68 $ 17,418 5.3
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to option activity during the three and six months ended June 30, 2021 and 2020 was as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 Weighted-average fair value of options granted $ 34.42 $ — $ 33.11 $ 23.05 Total intrinsic value of stock options exercised ($000s) $ 1,814 $ 2,351 $ 3,731 $ 6,371
Schedule of Non-vested Restricted Stock Activity	Non-vested restricted stock activity for the six months ended June 30, 2021 and 2020 is summarized below: Six Months Ended June 30, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 159 $ 90.71 138 $ 80.03 Granted 37 119.30 35 110.72 Vested (13) 87.33 (20) 67.59 Forfeited (2) 85.60 (1) 86.82 Non-vested balance as of June 30 181 $ 96.89 152 $ 89.22
Schedule of Non-vested Performance Share Activity	Non-vested performance share activity for the six months ended June 30, 2021 and 2020 is summarized below: Six Months Ended June 30, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 71 $ 91.99 70 $ 81.26 Granted 36 108.74 20 126.46 Vested (24) 70.64 (8) 104.15 Forfeited (11) 74.57 (11) 82.71 Non-vested balance as of June 30 72 $ 110.22 71 $ 91.99

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories at June 30, 2021 and December 31, 2020 consisted of the following: June 30, 2021 December 31, 2020 Raw materials $ 25,119 $ 24,536 Work in progress 9,682 3,050 Finished goods 43,532 43,034 Total inventories $ 78,333 $ 70,620

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment at June 30, 2021 and December 31, 2020 are summarized as follows: June 30, 2021 December 31, 2020 Land $ 11,988 $ 12,215 Building 88,224 86,873 Equipment 250,596 247,884 Construction in progress 37,941 31,240 388,749 378,212 Less: accumulated depreciation 160,460 150,116 Property, plant and equipment, net $ 228,289 $ 228,096

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets	Identifiable intangible assets with finite lives at June 30, 2021 and December 31, 2020 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at 6/30/2021 Gross Carrying Amount at 12/31/2020 Accumulated Amortization at 12/31/2020 Customer relationships & lists 10-20 $ 242,089 $ 165,886 $ 243,557 $ 158,051 Trademarks & trade names 2-17 43,169 27,112 43,208 24,974 Developed technology 5-12 20,351 14,210 20,437 13,693 Other 2-18 23,454 13,602 22,861 11,685 $ 329,063 $ 220,810 $ 330,063 $ 208,403

NET EARNINGS PER SHARE (Tables)

NET EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Reconciliation of the Net Earnings and Shares Used in Calculating Basic and Diluted Net Earnings Per Share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended Six Months Ended 2021 2020 2021 2020 Net Earnings - Basic and Diluted $ 22,731 $ 21,125 $ 46,142 $ 40,893 Shares (000s) Weighted Average Common Shares - Basic 32,232 32,180 32,243 32,158 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 419 290 410 334 Weighted Average Common Shares - Diluted 32,651 32,470 32,653 32,492 Net Earnings Per Share - Basic $ 0.71 $ 0.66 $ 1.43 $ 1.27 Net Earnings Per Share - Diluted $ 0.70 $ 0.65 $ 1.41 $ 1.26

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The segment information is summarized as follows: Business Segment Assets June 30, December 31, Human Nutrition & Health $ 721,428 $ 717,232 Animal Nutrition & Health 156,597 157,454 Specialty Products 194,140 190,449 Other and Unallocated (1) 101,441 100,708 Total $ 1,173,606 $ 1,165,843 Business Segment Net Sales Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 111,471 $ 97,428 $ 215,987 $ 192,936 Animal Nutrition & Health 54,481 46,344 105,629 94,985 Specialty Products 34,022 28,194 62,030 56,190 Other and Unallocated (2) 2,391 1,389 4,375 3,680 Total $ 202,365 $ 173,355 $ 388,021 $ 347,791 Business Segment Earnings Before Income Taxes Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 19,021 $ 15,497 $ 38,711 $ 27,632 Animal Nutrition & Health 3,561 6,430 8,617 14,474 Specialty Products 9,729 8,008 16,918 15,994 Other and Unallocated (2) (1,718) (3,018) (3,078) (4,905) Interest and other expense (574) (944) (1,166) (2,732) Total $ 30,019 $ 25,973 $ 60,002 $ 50,463 Depreciation/Amortization Three Months Ended Six Months Ended 2021 2020 2021 2020 Human Nutrition & Health $ 7,441 $ 8,015 $ 15,014 $ 15,859 Animal Nutrition & Health 1,816 1,793 3,580 3,548 Specialty Products 2,085 2,372 4,354 4,764 Other and Unallocated (2) 757 565 1,515 1,123 Total $ 12,099 $ 12,745 $ 24,463 $ 25,294 Capital Expenditures Six Months Ended 2021 2020 Human Nutrition & Health $ 8,883 $ 8,884 Animal Nutrition & Health 2,729 2,446 Specialty Products 1,448 958 Other and Unallocated (2) 66 87 Total $ 13,126 $ 12,375 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $466 and $700 for the three and six months ended June 30, 2021, respectively, and $746 and $2,018 for the three and six months ended June 30, 2020, respectively, and (ii) Unallocated amortization expense of $674 and $1,349 for the three and six months ended June 30, 2021, respectively, and $475 and $947 for the three and six months ended June 30, 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in the Company's consolidated statement of earnings.

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenues	The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended Six Months Ended 2021 2020 2021 2020 Product Sales $ 193,122 $ 163,038 $ 369,110 $ 330,603 Co-manufacturing 6,878 8,135 14,156 13,376 Bill and Hold — 395 — 395 Consignment 1,380 695 2,431 1,314 Product Sales Revenue 201,380 172,263 385,697 345,688 Royalty Revenue 985 1,092 2,324 2,103 Total Revenue $ 202,365 $ 173,355 $ 388,021 $ 347,791 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended Six Months Ended 2021 2020 2021 2020 United States $ 147,188 $ 122,236 $ 285,039 $ 249,145 Foreign Countries 55,177 51,119 102,982 98,646 Total Revenue $ 202,365 $ 173,355 $ 388,021 $ 347,791

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Cash paid during the six months ended June 30, 2021 and 2020 for income taxes and interest is as follows: Six Months Ended 2021 2020 Income taxes $ 12,493 $ 555 Interest $ 2,452 $ 2,580

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive income/(loss) were as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 Net foreign currency translation adjustment $ 1,524 $ 2,346 $ (4,619) $ 3,127 Net change of cash flow hedge (see Note 19 for further information) Unrealized gain (loss) on cash flow hedge 456 49 1,133 (3,884) Tax (105) 172 (270) 998 Net of tax 351 221 863 (2,886) Net change in postretirement benefit plan (see Note 14 for further information) Amortization of prior service cost 19 19 37 38 Amortization of gain (7) (13) (12) (26) Prior service credit — — (4) — Total before tax 12 6 21 12 Tax (4) 2 (6) 1 Adjustment (1) — — — (584) Net of tax and adjustment 8 8 15 (571) Total other comprehensive income (loss) $ 1,883 $ 2,575 $ (3,741) $ (330) (1) One time adjustment to the postretirement account.
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income/(loss) at June 30, 2021 and December 31, 2020 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2020 $ 7,653 $ (3,684) $ 204 $ 4,173 Other comprehensive income/(loss) (4,619) 863 15 (3,741) Balance June 30, 2021 $ 3,034 $ (2,821) $ 219 $ 432

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Cost	Net periodic benefit costs for such retirement medical plans were as follows: Six Months Ended 2021 2020 Service cost $ 43 $ 34 Interest cost 12 13 Amortization of prior service cost 37 38 Amortization of gain (12) (26) Net periodic benefit cost $ 80 $ 59 Six Months Ended 2021 2020 Service cost with interest to end of year $ 35 $ 52 Interest cost 7 10 Expected return on plan assets (18) (8) Amortization of gain 2 — Total net periodic benefit cost $ 26 $ 54

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases	Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at June 30, 2021 are as follows: Year July 1, 2021 to December 31, 2021 $ 2,118 2022 3,022 2023 2,381 2024 1,578 2025 972 2026 664 Thereafter 2,414 Total minimum lease payments $ 13,149

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of Right of Use Asset and Lease Liabilities	Right of use assets and lease liabilities at June 30, 2021 and December 31, 2020 are summarized as follows: Right of use assets June 30, 2021 December 31, 2020 Operating leases $ 7,108 $ 5,838 Finance leases 2,467 2,572 Total $ 9,575 $ 8,410 Lease liabilities - current June 30, 2021 December 31, 2020 Operating leases $ 2,126 $ 2,178 Finance leases 163 159 Total $ 2,289 $ 2,337 Lease liabilities - non-current June 30, 2021 December 31, 2020 Operating leases $ 5,005 $ 3,607 Finance leases 2,390 2,472 Total $ 7,395 $ 6,079
Schedule of Lease Cost	For the three and six months ended June 30, 2021 and 2020, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Six Months Ended 2021 2020 2021 2020 Lease Cost Operating lease cost $ 770 $ 736 $ 1,486 $ 1,477 Finance Lease cost Amortization of ROU asset 53 — 105 — Interest on lease liabilities 33 — 66 — Total finance lease 86 — 171 — Total lease cost $ 856 $ 736 $ 1,657 $ 1,477 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 749 $ 739 $ 1,488 $ 1,483 Operating cash flows from finance leases 33 — 66 — Financing cash flows from finance leases 39 — 78 — $ 821 $ 739 $ 1,632 $ 1,483 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 1,376 $ (107) $ 2,412 $ (98) Weighted-average remaining lease term - operating leases 4.43 years 5.01 years 4.43 years 5.01 years Weighted-average remaining lease term - finance leases 11.75 years n/a 11.75 years n/a Weighted-average discount rate - operating leases 3.9 % 4.6 % 3.9 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a 5.1 % n/a

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value of Derivative Instruments	As of June 30, 2021 and December 31, 2020, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative liabilities June 30, 2021 December 31, 2020 Interest rate swap $ 3,732 $ 4,865 Cross-currency swap 3,930 6,793 Derivative liabilities $ 7,662 $ 11,658
Schedule of Gains (Losses) on Hedging Instruments	Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and six months ended June 30, 2021 and 2020: Location within Statements of Comprehensive Income Three Months Ended Six Months Ended 2021 2020 2021 2020 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 351 $ 221 $ 863 $ (2,886) Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment (1,024) (1,514) 2,173 2,905 Total $ (673) $ (1,293) $ 3,036 $ 19

STOCKHOLDERS' EQUITY - Stock-Ba

STOCKHOLDERS' EQUITY - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Impact of stock-based compensation cost on net earnings	$ (2,547)	$ (1,756)	$ (4,569)	$ (3,419)
Expiration period of options granted			10 years
Shares available for future awards (in shares)	687,297		687,297
Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Minimum | Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			4 years
Restricted stock | Maximum | Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			4 years
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 444	310	$ 744	575
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 2,849	$ 2,010	$ 5,170	$ 3,926

STOCKHOLDERS' EQUITY - Stock Op

STOCKHOLDERS' EQUITY - Stock Options (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)			858	951
Granted (in shares)			129	145
Exercised (in shares)			(58)	(130)
Forfeited (in shares)			(2)	(4)
Canceled (in shares)			(1)	0
Outstanding at end of period (in shares)	926	962	926	962
Exercisable at end of period (in shares)	580	618	580	618
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)			$ 80.58	$ 68.18
Granted (in dollars per share)			119.12	111.94
Exercised (in dollars per share)			65.95	52.54
Forfeited (in dollars per share)			101.38	89.90
Canceled (in dollars per share)			74.57	0
Outstanding at end of period (in dollars per share)	$ 86.85	$ 76.78	86.85	76.78
Exercisable at end of period (in dollars per share)	$ 73.72	$ 66.68	$ 73.72	$ 66.68
Aggregate intrinsic value, outstanding, beginning of period			$ 29,735	$ 31,814
Aggregate intrinsic value, outstanding, end of period	$ 41,107	$ 19,915	41,107	19,915
Aggregate intrinsic value, exercisable, end of period	$ 33,398	$ 17,418	$ 33,398	$ 17,418
Weighted average remaining contractual term, outstanding			6 years 9 months 18 days	6 years 6 months
Weighted average remaining contractual term, exercisable			5 years 7 months 6 days	5 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield rate			0.50%	0.50%
Expected volatility rate			33.00%	26.00%
Risk-free interest rate			0.50%	1.40%
Expected term			4 years 10 months 24 days	3 years 8 months 12 days
Weighted-average fair value of options granted (in dollars per share)	$ 34.42	$ 0	$ 33.11	$ 23.05
Total intrinsic value of stock options exercised	$ 1,814	$ 2,351	$ 3,731	$ 6,371

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Unrecognized compensation cost	$ 19,796	$ 17,034
Period for unrecognized compensation cost to be recognized over	1 year 7 months 6 days
Estimated share-based compensation expense	$ 11,400
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	159	138
Granted (in shares)	37	35
Vested (in shares)	(13)	(20)
Forfeited (in shares)	(2)	(1)
Non-vested balance as of end of period (in shares)	181	152
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 90.71	$ 80.03
Granted (in dollars per share)	119.30	110.72
Vested (in dollars per share)	87.33	67.59
Forfeited (in dollars per share)	85.60	86.82
Non-vested balance as of end of period (in dollars per share)	$ 96.89	$ 89.22
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	71	70
Granted (in shares)	36	20
Vested (in shares)	(24)	(8)
Forfeited (in shares)	(11)	(11)
Non-vested balance as of end of period (in shares)	72	71
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 91.99	$ 81.26
Granted (in dollars per share)	108.74	126.46
Vested (in dollars per share)	70.64	104.15
Forfeited (in dollars per share)	74.57	82.71
Non-vested balance as of end of period (in dollars per share)	$ 110.22	$ 91.99
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	0.20%	1.40%
Dividend yield rate	0.60%	0.50%
Expected volatility rate	33.00%	24.00%
Initial TSR	11.70%	10.90%
Cliff vest	100.00%

STOCKHOLDERS' EQUITY - Repurcha

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)	3,763,038
Aggregate number of shares repurchased since inception (in shares)	2,654,520
Number of shares remaining in treasury (in shares)	66,055		76,084
Number of shares acquired under stock repurchase plan and subsequently reissued (in shares)	86,124	32,505
Treasury stock acquired, average cost (in dollars per share)	$ 125.81	$ 93.05

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 25,119	$ 24,536
Work in progress	9,682	3,050
Finished goods	43,532	43,034
Total inventories	$ 78,333	$ 70,620

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 388,749	$ 378,212
Less: accumulated depreciation	160,460	150,116
Property, plant and equipment, net	228,289	228,096
Land
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	11,988	12,215
Building
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	88,224	86,873
Equipment
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	250,596	247,884
Construction in progress
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 37,941	$ 31,240

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 527,148,000		$ 527,148,000		$ 529,463,000
Amortization of identifiable intangible assets	6,229,000	$ 6,985,000	12,713,000	$ 13,964,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	12,322,000		12,322,000
2022	23,092,000		23,092,000
2023	19,491,000		19,491,000
2024	10,652,000		10,652,000
2025	6,386,000		6,386,000
2026	5,054,000		5,054,000
Identifiable intangible assets with indefinite useful lives	$ 0	$ 0	$ 0	$ 0

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 329,063	$ 330,063
Accumulated amortization	220,810	208,403
Customer relationships & lists
Identifiable intangible assets [Abstract]
Gross carrying amount	242,089	243,557
Accumulated amortization	$ 165,886	158,051
Customer relationships & lists | Minimum
Identifiable intangible assets [Abstract]
Amortization period	10 years
Customer relationships & lists | Maximum
Identifiable intangible assets [Abstract]
Amortization period	20 years
Trademarks & trade names
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 43,169	43,208
Accumulated amortization	$ 27,112	24,974
Trademarks & trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization period	2 years
Trademarks & trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization period	17 years
Developed technology
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 20,351	20,437
Accumulated amortization	$ 14,210	13,693
Developed technology | Minimum
Identifiable intangible assets [Abstract]
Amortization period	5 years
Developed technology | Maximum
Identifiable intangible assets [Abstract]
Amortization period	12 years
Other
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 23,454	22,861
Accumulated amortization	$ 13,602	$ 11,685
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization period	2 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization period	18 years

EQUITY-METHOD INVESTMENT (Detai

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)vote	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Equity Method Investment, Summarized Financial Information [Abstract]
Percentage of operating expenses to be absorbed			66.66%
Percentage of production offtake			66.66%
St. Gabriel CC Company, LLC
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	66.66%		66.66%
Number of votes | vote			2
Loss relating to joint venture's expenses	$ 130	$ 142	$ 274	$ 280
Net return of capital	(28)		(15)
Capital contribution to investment		$ 131		$ 798
Carrying value of joint venture	$ 4,682		$ 4,682		$ 4,971
St. Gabriel CC Company, LLC | Eastman Chemical Company
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	33.34%		33.34%
Number of votes | vote			2

REVOLVING LOAN (Details)

REVOLVING LOAN (Details) - USD ($)	Jun. 27, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Line of Credit Facility [Abstract]
Outstanding balance		$ 123,569,000		$ 123,569,000		$ 163,569,000
Capitalized costs net of accumulated amortization		562,000		562,000		$ 703,000
Amortization expense pertaining to capitalized costs		$ 70,000	$ 70,000	$ 141,000	$ 141,000
Credit agreement
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 500,000,000
Interest rate		1.095%		1.095%
Commitment fee percentage				0.15%
Unused portion of revolving loan		$ 376,431,000		$ 376,431,000
Credit agreement | Minimum
Line of Credit Facility [Abstract]
Commitment fee percentage	0.15%
Credit agreement | Maximum
Line of Credit Facility [Abstract]
Commitment fee percentage	0.275%
Senior secured term loan
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 350,000,000
Payments for outstanding balance	210,750,000
Revolving credit facility
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 100,000,000
Installment payments required				$ 0

NET EARNINGS PER SHARE (Details

NET EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share, Basic and Diluted [Abstract]
Net Earnings - Basic and Diluted	$ 22,731	$ 23,411	$ 21,125	$ 19,768	$ 46,142	$ 40,893
Weighted average common shares - basic (in shares)	32,232,000		32,180,000		32,243,000	32,158,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)	419,000		290,000		410,000	334,000
Weighted average common shares - diluted (in shares)	32,651,000		32,470,000		32,653,000	32,492,000
Net earnings per share - basic (in dollars per share)	$ 0.71		$ 0.66		$ 1.43	$ 1.27
Net earnings per share - diluted (in dollars per share)	$ 0.70		$ 0.65		$ 1.41	$ 1.26
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)	153,868		377,573		304,324	212,271

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	24.30%	18.70%	23.10%	19.00%
Unrecognized tax benefits	$ 5,465		$ 5,465		$ 5,335
Accrued interest and penalties related to unrecognized tax benefits	$ 1,971		$ 1,971		$ 1,845

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
	Jun. 30, 2021numberOfFillingFacilitynumberOfReportableSegment
Segment Reporting [Abstract]
Number of business segments | numberOfReportableSegment	3
Number of filling facilities | numberOfFillingFacility	5

SEGMENT INFORMATION - Business

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Segment information [Abstract]
Assets	$ 1,173,606	$ 1,165,843
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Assets	721,428	717,232
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Assets	156,597	157,454
Operating segments | Specialty Products
Segment information [Abstract]
Assets	194,140	190,449
Other and unallocated
Segment information [Abstract]
Assets	$ 101,441	$ 100,708

SEGMENT INFORMATION - Busines_2

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information [Abstract]
Net sales	$ 202,365	$ 173,355	$ 388,021	$ 347,791
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Net sales	111,471	97,428	215,987	192,936
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Net sales	54,481	46,344	105,629	94,985
Operating segments | Specialty Products
Segment information [Abstract]
Net sales	34,022	28,194	62,030	56,190
Other and unallocated
Segment information [Abstract]
Net sales	$ 2,391	$ 1,389	$ 4,375	$ 3,680

SEGMENT INFORMATION - Busines_3

SEGMENT INFORMATION - Business Segment Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information [Abstract]
Earnings before income taxes	$ 30,019	$ 25,973	$ 60,002	$ 50,463
Interest and other (expense)	(574)	(944)	(1,166)	(2,732)
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	19,021	15,497	38,711	27,632
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	3,561	6,430	8,617	14,474
Operating segments | Specialty Products
Segment information [Abstract]
Earnings before income taxes	9,729	8,008	16,918	15,994
Other and unallocated
Segment information [Abstract]
Earnings before income taxes	(1,718)	(3,018)	(3,078)	(4,905)
Interest and other expense
Segment information [Abstract]
Interest and other (expense)	$ (574)	$ (944)	$ (1,166)	$ (2,732)

SEGMENT INFORMATION - Depreciat

SEGMENT INFORMATION - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information [Abstract]
Depreciation and amortization	$ 12,099	$ 12,745	$ 24,463	$ 25,294
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	7,441	8,015	15,014	15,859
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	1,816	1,793	3,580	3,548
Operating segments | Specialty Products
Segment information [Abstract]
Depreciation and amortization	2,085	2,372	4,354	4,764
Other and unallocated
Segment information [Abstract]
Depreciation and amortization	$ 757	$ 565	$ 1,515	$ 1,123

SEGMENT INFORMATION - Capital E

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information [Abstract]
Capital expenditures			$ 13,126	$ 12,375
Amortization of identifiable intangible assets	$ 6,229	$ 6,985	12,713	13,964
Other and unallocated
Segment information [Abstract]
Capital expenditures			66	87
Transaction and integration costs, ERP implementation costs, and unallocated legal fees	466	746	700	2,018
Amortization of identifiable intangible assets	$ 674	$ 475	1,349	947
Human Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			8,883	8,884
Animal Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			2,729	2,446
Specialty Products | Operating segments
Segment information [Abstract]
Capital expenditures			$ 1,448	$ 958

REVENUE - Schedule of Disaggreg

REVENUE - Schedule of Disaggregation of Revenues (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)numberOfRevenueSubstream	Jun. 30, 2020USD ($)
Revenue [Abstract]
Net sales	$ 202,365	$ 173,355	$ 388,021	$ 347,791
United States
Revenue [Abstract]
Net sales	147,188	122,236	285,039	249,145
Foreign Countries
Revenue [Abstract]
Net sales	55,177	51,119	102,982	98,646
Product Sales
Revenue [Abstract]
Net sales	193,122	163,038	369,110	330,603
Co-manufacturing
Revenue [Abstract]
Net sales	6,878	8,135	14,156	13,376
Bill and Hold
Revenue [Abstract]
Net sales	0	395	0	395
Consignment
Revenue [Abstract]
Net sales	1,380	695	2,431	1,314
Product Sales Revenue
Revenue [Abstract]
Net sales	201,380	172,263	$ 385,697	345,688
Number of sub-streams of revenue | numberOfRevenueSubstream			4
Royalty Revenue
Revenue [Abstract]
Net sales	$ 985	$ 1,092	$ 2,324	$ 2,103

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 12,493	$ 555
Interest	$ 2,452	$ 2,580

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Changes in accumulated other comprehensive income (loss) [Abstract]
Net foreign currency translation adjustment	$ 1,524		$ 2,346		$ (4,619)	$ 3,127
Unrealized gain (loss) on cash flow hedge	456		49		1,133	(3,884)
Tax	(105)		172		(270)	998
Net of tax	351		221		863	(2,886)
Net change in postretirement benefit plan (see Note 14 for further information)
Amortization of prior service cost	19		19		37	38
Amortization of gain	(7)		(13)		(12)	(26)
Prior service credit	0		0		(4)	0
Total before tax	12		6		21	12
Tax	(4)		2		(6)	1
Adjustment	0		0		0	(584)
Net of tax and adjustment	8		8		15	(571)
Other comprehensive income (loss)	1,883	$ (5,624)	2,575	$ (2,905)	(3,741)	(330)
Gain (loss) related to net investment hedge	(1,024)		(1,514)		2,173	2,905
Tax expense (benefit) on net investment hedge	$ (336)		$ (260)		$ 690	$ 914

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 849,492	$ 828,233	$ 766,271	$ 743,667	$ 828,233	$ 743,667
Other comprehensive income/(loss)	1,883	(5,624)	2,575	(2,905)	(3,741)	(330)
Ending balance	869,642	849,492	792,523	766,271	869,642	792,523
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		7,653			7,653
Other comprehensive income/(loss)					(4,619)
Ending balance	3,034				3,034
Cash flow hedge
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(3,684)			(3,684)
Other comprehensive income/(loss)					863
Ending balance	(2,821)				(2,821)
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		204			204
Other comprehensive income/(loss)					15
Ending balance	219				219
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(1,451)	4,173	(8,469)	(5,564)	4,173	(5,564)
Other comprehensive income/(loss)	1,883	(5,624)	2,575	(2,905)	(3,741)
Ending balance	$ 432	$ (1,451)	$ (5,894)	$ (8,469)	$ 432	$ (5,894)

EMPLOYEE BENEFIT PLANS (Details

EMPLOYEE BENEFIT PLANS (Details) $ in Thousands	Jan. 01, 2021numberOfPlan	Dec. 31, 2020USD ($)numberOfPlan	Jun. 30, 2021USD ($)numberOfPlan	Jun. 30, 2020USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | numberOfPlan	1	2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Deferred compensation liability		$ 3,581	$ 5,714
Related rabbi trust assets		3,581	$ 5,714
Postretirement Medical Plan
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit plans | numberOfPlan			2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			$ 43	$ 34
Interest cost			12	13
Amortization of prior service cost			37	38
Amortization of gain			12	26
Net periodic benefit cost			80	59
Benefit obligation		1,374	1,429
Historical cash payments for retirement medical plan claims per year (less than)			100
Defined Benefit Pension Plan | Chemogas Defined Pension Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			35	52
Interest cost			7	10
Expected return on plan assets			(18)	(8)
Amortization of gain			2	0
Net periodic benefit cost			26	$ 54
Benefit obligation		$ 950	$ 945

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Jun. 30, 2021USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
July 1, 2021 to December 31, 2021	$ 2,118
2022	3,022
2023	2,381
2024	1,578
2025	972
2026	664
Thereafter	2,414
Total minimum lease payments	$ 13,149

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)numberOfFinancialInstrument	Dec. 31, 2020USD ($)
Fair value of financial instruments [Abstract]
Number of financial instruments held for trading purposes | numberOfFinancialInstrument	0
Related rabbi trust assets	$ 5,714	$ 3,581
Cross-currency swap
Fair value of financial instruments [Abstract]
Derivative liabilities	3,930	6,793
Interest rate swap
Fair value of financial instruments [Abstract]
Derivative liabilities	3,732	4,865
Derivative liability
Fair value of financial instruments [Abstract]
Derivative liabilities	7,662	11,658
Money market funds | Level 1
Fair value of financial instruments [Abstract]
Cash and cash equivalents	$ 814	$ 817

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Related party transactions [Abstract]
Finished goods received from related party recorded in cost of goods sold	$ 5,210	$ 3,020	$ 9,601	$ 6,741
Receivable from related party	7,423		7,423		$ 2,809
Payables to related parties	5,182		5,182		2,239
Related party receivable related to non-contractual monies					72
Related party payable related to non-contractual monies	296		296		$ 296
Services provided
Related party transactions [Abstract]
Revenue from related party	920	857	1,747	1,710
Raw materials sold
Related party transactions [Abstract]
Revenue from related party	$ 6,580	$ 2,903	$ 12,042	$ 7,614

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)numberOfTranche	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Number of tranches | numberOfTranche			4
Finance lease liability	$ 2,553		$ 2,553		$ 2,631
Rent expense charged to operations under lease agreements	$ 770	$ 736	$ 1,486	$ 1,477
Years 1 and 2
Lessee, Lease, Description [Line Items]
Discount rate	1.45%		1.45%
Years 1 and 2 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	1 year		1 year
Years 1 and 2 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	2 years		2 years
Years 3 and 4
Lessee, Lease, Description [Line Items]
Discount rate	2.04%		2.04%
Years 3 and 4 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	3 years		3 years
Years 3 and 4 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	4 years		4 years
Years 5 and 9
Lessee, Lease, Description [Line Items]
Discount rate	2.38%		2.38%
Years 5 and 9 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	5 years		5 years
Years 5 and 9 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	9 years		9 years
Years more than 10
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	10 years		10 years
Discount rate	3.10%		3.10%

LEASES - Right-of-Use Assets an

LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Right of use assets
Operating Lease - ROU	$ 7,108	$ 5,838
Finance Leases - ROU	2,467	2,572
Total right-of-use assets	9,575	8,410
Operating leases liabilities - current	2,126	2,178
Finance leases liabilities - current	163	159
Total lease liabilities, current	2,289	2,337
Operating leases liabilities - non-current	5,005	3,607
Finance leases liabilities - non-current	2,390	2,472
Total lease liabilities, non-current	$ 7,395	$ 6,079
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Total right-of-use assets	Total right-of-use assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities, current	Total lease liabilities, current
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities, non-current	Total lease liabilities, non-current
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Total right-of-use assets	Total right-of-use assets
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities, current	Total lease liabilities, current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities, non-current	Total lease liabilities, non-current

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lease Cost
Operating lease cost	$ 770	$ 736	$ 1,486	$ 1,477
Amortization of ROU asset	53	0	105	0
Interest on lease liabilities	33	0	66	0
Total finance lease	86	0	171	0
Total lease cost	856	736	1,657	1,477
Operating cash flows from operating leases
Operating cash flows from operating leases	749	739	1,488	1,483
Operating cash flows from finance leases	33	0	66	0
Financing cash flows from finance leases	39	0	78	0
Cash flows from operating and finance leases	821	739	1,632	1,483
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$ 1,376	$ (107)	$ 2,412	$ (98)
Weighted-average remaining lease term - operating leases	4 years 5 months 4 days	5 years 3 days	4 years 5 months 4 days	5 years 3 days
Weighted-average discount rate - operating leases	3.90%	4.60%	3.90%	4.60%
Weighted-average discount rate - finance leases	5.10%		5.10%
Finance Lease, Weighted Average Remaining Lease Term	11 years 9 months		11 years 9 months

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	May 28, 2019
Interest rate swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ (534)	$ (430)	$ (1,055)	$ (551)
Designated as hedging instrument | Interest rate swap
Derivative [Line Items]
Notional amount of derivatives					$ 108,569
Designated as hedging instrument | Interest rate swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate					2.05%
Designated as hedging instrument | Cross-currency swap
Derivative [Line Items]
Notional amount of derivatives					$ 108,569
Designated as hedging instrument | Cross-currency swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ 563	$ 581	$ 1,119	$ 1,144
Designated as hedging instrument | Cross-currency swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate					0.00%
Designated as hedging instrument | Cross-currency swap | Receive-fixed interest rate
Derivative [Line Items]
Fixed interest rate					2.05%

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Derivative financial instruments, liabilities
Derivative Liability [Abstract]
Derivative liabilities	$ 7,662	$ 11,658
Interest rate swap
Derivative Liability [Abstract]
Derivative liabilities	3,732	4,865
Cross-currency swap
Derivative Liability [Abstract]
Derivative liabilities	$ 3,930	$ 6,793

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	$ (1,024)	$ (1,514)	$ 2,173	$ 2,905
Gains and losses from hedging instruments recognized in AOCI	(673)	(1,293)	3,036	19
Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedge (interest rate swap), net of tax	351	221	863	(2,886)
Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	$ (1,024)	$ (1,514)	$ 2,173	$ 2,905